Background: In this study, we developed integrative, personalized prognostic models for breast cancer recurrence and overall survival (OS) that consider receptor subtypes, epidemiological data, quality of life (QoL), and treatment. Methods: A total of 15 314 women with stage I to III invasive primary breast cancer treated at The University of Texas MD Anderson Cancer Center between 1997 and 2012 were used to generate prognostic models by Cox regression analysis in a two-stage study. Model performance was assessed by calculating the area under the curve (AUC) and calibration analysis and compared with Nottingham Prognostic Index (NPI) and PREDICT. Results: Host characteristics were assessed for 10 809 women as the discovery population (median follow-up ¼ 6.09 years, 1144 recurrence and 1627 deaths) and 4505 women as the validation population (median follow-up ¼ 7.95 years, 684 recurrence and 1095 deaths). In addition to the known clinical/pathological variables, the model for recurrence included alcohol consumption while the model for OS included smoking status and physical component summary score. The AUCs for recurrence and OS were 0.813 and 0.810 in the discovery and 0.807 and 0.803 in the validation, respectively, compared with AUCs of 0.761 and 0.753 in discovery and 0.777 and 0.751 in validation for NPI. Our model further showed better calibration compared with PREDICT. We also developed race-specific and receptor subtype-specific models with comparable AUCs. Racial disparity was evident in the distributions of many risk factors and clinical presentation of the disease. Conclusions: Our integrative prognostic models for breast cancer exhibit high discriminatory accuracy and excellent calibration and are the first to incorporate receptor subtype and epidemiological and QoL data.
Breast cancer is a heterogeneous disease with distinct prognoses. To help establish guidelines for clinical decision-making with regard to personalized management of breast cancer, a number of prognostic models focusing on clinical/pathological and, recently, human epidermal growth factor receptor 2 (HER2) and estrogen receptor (ER) status have been developed since the early 1980s (1) (2) (3) (4) (5) (6) (7) (8) (9) . Currently, guidelines have been published on a wealth of tumor-based receptor markers (10) (11) (12) (13) (14) (15) (16) in determining prognosis and making decisions regarding adjuvant chemotherapy for early-stage hormone receptor-positive and HER2-negative breast cancer (17) . However, validation of these published prognostic models using external patient populations has shown only modest discriminatory accuracy (range ¼ 0.59-0.78) (3) (4) (5) (18) (19) (20) . Therefore, a large amount of variability in breast cancer clinical outcomes remains unexplained.
Progesterone receptor (PR) was used in combination with ER and HER2 to define receptor subtypes including HmR-positive (ERþ or PRþ, HER2-), HER2-positive (HER2þ), and triple-negative (ER-, PR-, HER2-). The inclusion of receptor subtype, patients' demographics, and health-related quality of life (QoL) in the model may improve model performance. These factors were rarely accounted for by the published breast cancer prognostic models. Importantly, racial disparities in breast cancer prognosis are well documented. Despite this, most of the existing models were developed based on white patients. Hence, performance of these models in other racial/ethnic groups is still unclear.
Using a comprehensive database containing breast cancer patients' clinical/pathological, epidemiological, and QoL data carefully compiled for over 20 years at The University of Texas MD Anderson Cancer Center (UTMDACC), we aimed to improve the prediction of breast cancer outcomes by developing models overall, as well as models applicable to patients with nonEuropean ancestry and specific receptor subtype. With the large minority population, we also examined racial/ethnic disparities in terms of risk factors and clinical characteristics of the disease.
Methods

Patient Population and Data Collection
This study included 15 314 women identified from the Breast Medical Oncology Institutional Database at UTMDACC and diagnosed with stage I to III invasive primary breast cancer between 1997 and 2012. To minimize the potential effects of referral bias, models were developed using the 10 809 study participants who met National Comprehensive Cancer Network (NCCN) criteria (21, 22) . These criteria defined eligible subjects who were age 18 years or older and had newly diagnosed breast cancer, had confirmed histology as defined by the American Joint Committee on Cancer (AJCC), and had received some or all forms of primary breast cancer treatment (surgery, chemotherapy, or hormone therapy). Patients with a history of breast cancer were eligible if they did not have a history of distant metastases and met the aforementioned criteria. Patients with a history of other cancer were eligible if they did not have a history of distant metastases or evidence of relapse and met the aforementioned criteria. The remaining 4505 women were used as the validation population. Epidemiologic and demographic data were collected by selfadministered questionnaires at the time of registration and within one year of diagnosis. Patients who drank alcoholic beverages (beer, wine, and liquor) regularly (at least one drink per month) were considered alcohol drinkers. Short Form 12 (SF12) questionnaires were collected at the same time as epidemiologic questionnaires and used to construct QoL variables including physical component summary (PCS) and mental component summary (MCS) scores. Clinical and follow-up data were abstracted from the patient's medical records. Written informed consent was obtained from study participants, and the study was approved by UTMDACC's Institutional Review Board.
Statistical Analysis
The end points were recurrence (defined as the local, regional, or distant metastatic recurrence) and overall survival (OS), and we predicted the likelihood of recurrence or survival within a five-year period. For recurrence, patients who died or who were alive at the last follow-up without evidence of recurrence were censored. Time to recurrence was defined as the time from the date of diagnosis to the date of first documented recurrence, the date of last follow-up, the date of death, or five years after diagnosis, whichever came first. Similarly, OS was defined as the time from the date of diagnosis to the date of death, the date of latest follow-up, or five years after diagnosis, whichever came first. The assumption of proportional hazard was tested by the methods of Therneau and Grambsch. Prognostic factors identified through univariate Cox analysis (Supplementary Tables 1  and 2 , available online) were subjected to backward stepwise Cox proportional hazards regression analysis to identify statistically significant prognostic factors (P < .05, Wald test) to be included in the final models. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for each factor. Prognostic models for recurrence and OS were generated by initiating the model with clinical/pathological variables, then sequentially incorporating epidemiological variables. Interaction between variables was assessed by adding interaction variable to the Cox model. Significance was checked with Bonferroni adjustment for multiple comparisons (P < .05/number of tests). We assessed model performance by generating receiver operating characteristic (ROC) curves and estimating area under the ROC curves (AUC) for our models and Nottingham Prognostic Index (NPI) (1). We assessed model calibration by generating calibration plot using 100 bootstrap runs to estimate the 95% confidence intervals. We compared the predicted and observed five-year events for our models and PREDICT (4) and used test of proportion for the equality of predicted and observed events. Predicted pure risk of developing the event was estimated using the equation
b j x j Þ . The differences in distribution of patient characteristics among race/ethnic subgroups were assessed by Pearson Chi-square test. Statistical analyses and modeling were performed using SAS (version 9.2; SAS Institute, Cary, NC), STATA (version 14; Stata Co., College Station, TX), and R software packages. All statistical tests were two-sided unless otherwise indicated, and a P value of less than .05 was considered statistically significant.
Results
Study Population Characteristics
The discovery population (demoþclinical) included a total of 10 809 women (1144 recurrence, 1627 deaths) with a median follow-up of 6.09 years and mean age of 54. Figure 1 , A-C. Good concordance and improvement in AUC was observed for the full model in both discovery and validation data with AUCs of 0.813 and 0.807 ( Figure 2, A and B) , respectively, although there was little improvement in AUC compared with the clinic model. AUCs for NPI in the the discovery and validation data were 0.761 and 0.777, respectively. We also observed good model calibration for the full model (Supplementary Table 3 , available online).
We also generated multivariable risk prognostic models for breast cancer recurrence by receptor subtypes (Table 2 ) and by race (Table 3 ). For the subtype-specific models, cancer detection mode, nuclear grade, tumor size, and number of positive nodes were consistently associated in all the subtype-specific models, while age, histology, LVI, and alcohol consumption were in the HmR-positive and triple-negative models, race/ethnicity and diagnosis year were in the HmR and HER2-positive models, and chemotherapy was in the HER2-positive model. For race-specific models, number of positive nodes and adjuvant hormone therapy showed consistent associations, while age, LVI, and receptor subtype were in the white model; histology was in the African American model; cancer detection mode, nuclear grade, and tumor size were in the white and African American models; and diagnosis year and alcohol consumption were in the white and Hispanic models.
Prognostic Model for Breast Cancer OS
As shown in Supplementary Table 4 (available online), the final OS demoþclinical models included terms for age, race/ethnicity, detection mode, nuclear grade, tumor size, number of positive nodes, LVI, receptor subtype, chemotherapy, and adjuvant hormonal therapy. Smoking status and PCS score were identified in the demoþclinicalþEPIþQoL model. The OS curve for full model by selected factors is shown in Figure 1 Table 3 , available online), while PREDICT overestimated the five-year death for the overall and the majority of subgroups in the discovery data and for the triple-negative subgroup in the validation data.
Additional analysis for multivariable risk prognostic models by receptor subtypes and by race was performed (Supplementary Tables 5 and 6 , available online). For subtypespecific models, tumor size and number of positive nodes had consistent association, while age, race/ethnicity, and nuclear grade were in the HmR-positive and triple-negative models, menopausal status and prior cancer were in the HER2-positive model, cancer detection mode and adjuvant hormone therapy were in the HmR and HER2-positive models, LVI was in the triple-negative model, and chemotherapy and PCS score were in the HmR-positive model. For the race-specific model, nuclear grade, tumor size, number of positive nodes, and adjuvant hormone therapy exhibited consistent association, while age, LVI, chemotherapy, and smoking status were in the white model, cancer detection mode and receptor subtype were the in the white and African American models, and PCS score was in the white and Hispanic models.
Application of Prognostic Model for Personalized Risk Prediction
We used the full models to predict pure five-year risk of recurrence and death using hypothetical patients age 40 and 65 years with various risk profiles for HmR-positive and triple-negative breast cancer. For a patient age 40 years with HmR-positive breast cancer and a lowest-risk profile, predicted five-years risk of recurrence was 1.5% (95% CI ¼ 0.9% to 2.0%) for African American, 1.0% (95% CI ¼ 0.6% to 1.3%) for white, 0.9% (95% CI ¼ 0.4% to 1.4%) for Asian/Pacific Islanders, and 0.8% (95% CI ¼ 0.4% to 1.1%) for Hispanic ( Figure 3 ). With the risk profiles changed to diagnosis years 1997-2002, cancer detected by symptoms, tumor size 4-5 cm, nuclear grade III, presence of LVI, five to eight positive nodes, and nonalcohol drinking, predicted fiveyear risk of recurrence increased to 75.0% (95% CI ¼ 55.6% to 85.9%) for African American, 59.8% (95% CI ¼ 42.0% to 72.1%) for white, 57.7% (95% CI ¼ 33.4% to 73.1%) for Asian/Pacific Islanders, and 51.4% (95% CI ¼ 33.2% to 64.6%) for Hispanic.
For a patient age 40 years with HmR-positive breast cancer, predicted five-year risk of death was 1.2% (95% CI ¼ 0.6% to 1.9%) for African American, 0.8% (95% CI ¼ 0.4% to 1.2%) for white, 0.8% (95% CI ¼ 0.2% to 1.4%) for Asian/Pacific Islanders, and 0.5% (95% CI ¼ 0.2% to 0.8%) for Hispanic with lowest-risk profile (Supplementary Figure 1 , available online). When the risk profiles changed to breast cancer detected by symptoms, tumor size 2-3 cm, nuclear grade III, presence of LVI, and three to four positive nodes, predicted five-year risk of death increased to 45.5% (95% CI ¼ 21.9% to 61.9%) for African American, 32.7% (95% CI ¼ 16.4% to 45.7%) for white, 31.7% (95% CI ¼ 6.9% to 49.8%) for Asian/Pacific Islanders, and 20.7% (95% CI ¼ 7.8% to 31.8%) for Hispanic.
Racial/Ethnic Disparities
The highest percentage of recurrence and death was observed for African American women (recurrence ¼ 17.7%; death ¼ 22.3%), followed by white (recurrence ¼ 9.8%; death ¼ 15.4%), Hispanic (recurrence ¼ 10.1%; death ¼ 11.0%), and Asian/Pacific women (recurrence ¼ 8.1%; death ¼ 7.1%). The distributions of the demographic, clinical/pathological, epidemiological, and QoL variables in the discovery population among racial/ethnic subgroups are shown in Table 4 . We observed statistically significant racial/ethnic disparities for the majority of these variables (Table 4) , except for LVI, although statistically significant interaction of LVI with race/ethnicity was observed for risk of death (P ¼ .04, data not shown). For example, African American women were more likely to be obese (57.3% having BMI ! 30 kg/m 2 ) compared with 13.5% to 36.6% for other races/ethnicities. African American women were more likely (23.6%) to be diagnosed with triple-negative breast cancer 
Discussion
This is the first large-scale study to incorporate epidemiological characteristics and QoL data to the breast cancer prognosis model. Our models, which were developed using the large patient population at UTMDACC, had AUCs of 0.813 for recurrence and 0.810 for survival in the discovery population. The models' high discriminatory accuracy was further confirmed by AUCs of 0.807 for recurrence and 0.803 for survival in the validation population. Calibration analysis demonstrated the good agreement between the predicted and observed five-year events in both the discovery and validation populations. Further, our models have improved AUCs compared with NPI and better calibrations compared with PREDICT. Using the large patient population, we published for the first time separate models for racial/ethnic subgroups and found racial/ethnic disparities across majorities of demographic, clinical/pathological, epidemiological, and QoL variables. To date, considerable effort has gone into the development of prognostic models for breast cancer clinical outcomes, particularly to individualize treatment recommendations. Earlier analyses focused on clinical and pathological factors while recent studies included individual receptor status in an effort to more precisely predict of patients' outcome, especially in the context of specific therapies. Nevertheless, no prognostic model for breast cancer outcomes currently uses the receptor subtype information. Our study showed that triple-negative breast 
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cancer patients have a statistically significantly increased risk of recurrence and death, while HER2-positive breast cancer patients have improved OS when compared with HmR-positive breast cancer patients. Many studies have shown racial/ethnic difference in breast cancer recurrence and survival (24) (25) (26) . The racial/ethnic disparities in clinical/pathological variables, treatment, family history of breast cancer, and QoL have also been studied (27) (28) (29) (30) , but few studies have examined the racial/ethnic disparities associated with smoking, alcohol consumption, and personal history of cancer. In this study, we demonstrated racial/ethnic disparities in almost all variables and incorporated race/ethnicity into breast cancer prognostic models. It is also noteworthy that, in comparison with white women, Hispanic women exhibited a consistently and statistically significantly reduced risk of death, while African American women exhibited a statistically significantly increased risk of recurrence and death. Therefore, the difference between the prognosis of African American and white patients could not be explained by the clinical/pathological differences. Further examination for the interaction of race/ethnicity with other factors found statistically significant interactions with presence of lymph or vascular invasion for risk of death and diagnosis year for risk of recurrence. However, they did not remain statistically significant after Bonferroni correction for multiple comparisons. 
Further, compared with existing models, our models incorporated many more additional epidemiological variables as independent prognostic factors including race/ethnicity, alcohol consumption, and smoking status. Prior meta-analyses have reported statistically significant associations between alcohol consumption and a reduced risk of death (31) and between smoking and an increased risk of death (32) . However, the association between alcohol consumption and the risk of recurrence has previously been unclear (31, 33, 34) . Our study suggested that alcohol consumption protects against recurrence. In addition, the association between smoking and a greater risk of death was confirmed by our study.
Health-related QoL has a profound impact on an individual's health. A statistically significant association between physical functioning and survival has been reported by several studies (35) (36) (37) (38) (39) , while other studies have found no statistically significant association (40) (41) (42) . The discrepancy in these findings may be attributed to the differences in QoL instruments, the timing of QoL assessments, racial/ethnic background, breast cancer patient characteristics, and the type of study (single-or multiinstitution), etc. In this study, we found that a low PCS score was associated with a statistically significantly increased risk of death. Therefore, our study provided evidence for the effect of physical well-being and illustrated the disparity in QoL among breast cancer patients.
Our models were developed with a large patient population with discovery and validation phases. Other more overt biases exist such as the use of adjuvant therapy (particularly chemotherapy) in higher-risk patients. Therefore, external validation in independent and diverse patient populations is also needed before our models can be applied in the clinical setting. Further, incorporation of epidemiological and QoL variables into our final models appears to marginally improve the models' discriminatory accuracy compared with clinic models, consistent with the observation from another study (43) . However, calibration analysis showed that full models were well calibrated for almost all the subgroup analysis except for two scenarios, while the clinic model did not have good calibration for 10 scenarios. Decision curve analysis further demonstrated higher net benefit for the full model compared with the clinical model. Because UTMDACC is a tertiary cancer center, patients who are not initially treated at UTMDACC and have poor prognostic features, such as tumor progression during neoadjuvant chemotherapy, among many other reasons, will further seek treatment at UTMDACC, as opposed to those who do not have these poor prognostic features. Therefore, there is a potential for referral bias. We focused the discovery data on patients who met NCCN criteria in order to broaden the applicability of the study in a hospital setting and used the remaining patients as validation data to examine whether the models are applicable to a different patient population with more aggressive disease. However, because only data from a single institution was used, it may limit the potential generalizability to external populations, and further validations in external populations are needed in order to generalize our findings. The median age of our patient population was about 10 years younger than that of overall US breast cancer population, and our populations also had a higher-thanaverage number of triple-negative and HER2-positive breast cancers. Also, the treatment plan might change during the study period, which could influence the patient prognosis, and in this retrospective analysis we did not have access to the reasons why patients received their specific treatments, although treatment of patients from single institution might be more homogeneous. We combined the locoregional and distant 
recurrence as overall recurrence because of the small number of events for locoregional recurrence. The results for distant recurrence were similar to overall recurrence in the univariate analysis (data not shown).
In conclusion, we have developed and validated prognostic models for early-stage breast cancer patients by adding, for the first time, receptor subtype and epidemiological and QoL variables. Our models have high discriminatory accuracy and excellent calibration. We have also demonstrated the health and well-being disparities between breast cancer patients of different racial/ethnic identifies.
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